PATENT CLAIM ANALYSIS

Application Number: 15968074
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-08
Patent Classification: ["514", "101000"]

Abstract:
Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.

Claim (Index 43):
The method of  claim 42 , wherein the neurodegenerative disease is selected from the group consisting of amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease, dementia with Lewy Bodies (DLB), schizophrenia, pain, epilepsy, stroke, and traumatic brain injury (TBI).

Metadata:
- Claim Count in Document: 14.0
- Percentile: 93.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15502105', '15502009', '15885258', '15385490', '15795906']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7334745184644376
- 35 USC 102 Novelty (BERT): 0.5891564078673437
- Combined Prediction Score: 0.7190427074047282
- Mean Citation Score: 288.05655399999995
- Max Citation Score: 531.9182
- Similarity Product: 390.4000413326741

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test